Israel's cannabis framework is medical-only, administered by the Ministry of Health, and built on three decades of incremental reform rather than a single legalising act. Understanding where the rules stand in 2026 means tracing how they got here — and which fights are still unresolved.
The legal baseline
Cannabis remains a controlled substance under Israeli law. There is no legal recreational market; possession of small amounts for personal use has been partly decriminalised and handled through administrative fines rather than criminal prosecution, but supply and consumption outside the medical system remain prohibited. Everything legal flows through the Ministry of Health's Medical Cannabis Unit (often referred to by the acronym IMCA / the Hebrew "Yakar"), which issues licences, sets standards and approves products.
A timeline of medical cannabis reform
1992 — first medical approvals. Israel first permitted medical cannabis use in 1992, with permits issued to individual patients meeting predefined criteria. For most of the following two decades the program was small and physician-gatekept.
2007–2013 — slow, structured growth. A formal program took shape over these years, with the Health Ministry centralising oversight. By December 2013 there were 10,750 active licences, and prescribing authority was carefully limited to a small roster of specialist physicians for approved indications.
June 2016 — the "medicalization" reform. The pivotal moment was government resolution #1587, the formal "medicalization" outline. At that point there were about 19,932 active licences. The reform introduced a suite of pharmaceutical-style standards governing the whole supply chain — IMC-GAP for cultivation, IMC-GMP for manufacturing, IMC-GDP for distribution and storage, and IMC-GSP for security. This is what turned Israeli medical cannabis from a patchwork of permits into a regulated, standards-based industry, and it underpins the country's export ambitions.
2019 — per-product pricing. The program moved to a per-product pricing model, replacing the earlier flat-rate arrangement and reshaping how patients pay for treatment.
2020 — decentralised prescribing. Prescription authority was broadened to trained physicians beyond the original narrow specialist roster, accelerating patient growth.
2024 — the HMO-led reform. The most consequential recent change moved prescribing into the public health maintenance organisations (HMOs). Patients with chronic pain or PTSD continue to receive Ministry licences, while many other recognised indications shifted to prescriptions issued through the health funds. The reform was intended to integrate cannabis into mainstream care — but stricter gatekeeping also helped trigger the program's first sustained decline in patient numbers.
The two reforms now in play
The regulatory story heading into 2026 is dominated by two contested proposals, both of which would significantly reshape the market.
Import tariffs on Canadian cannabis
Because Israel imports a large share of its flower, trade policy is cannabis policy. The Ministry of Economy, under Minister Nir Barkat, advanced an anti-dumping duty of up to 165% on Canadian imports after concluding that Canadian producers were selling into Israel below cost. The proposal carried producer-specific rates and was fiercely opposed by importers and the Health Ministry, who warned of higher patient prices and a boost to the illicit market. Finance Minister Bezalel Smotrich formally rejected the tariffs, and with legal backing the matter appears settled for now — though it remains the clearest example of how interministerial conflict shapes the sector.
The proposed smokable-cannabis phase-out
A Health Ministry committee chaired by Dr. Gilad Bodenheimer recommended a sweeping tightening of the program, the headline being a three-year phase-out of smoked cannabis, with exceptions only for patients over 75 and the terminally ill. The committee argued that smoking delivers inconsistent dosing that cannot be properly monitored, and noted that most countries permitting medical cannabis no longer allow smoking. It also recommended moving essentially all prescribing into the health funds, tightening PTSD criteria, and requiring a physician meeting to renew prescriptions beyond six months. Because dried flower accounts for the overwhelming majority of usage, the proposal would amount to a structural reset of the market.
Crucially, it has not taken effect. Health Minister Haim Katz froze implementation after a professional briefing, instructing the ministry to halt work on the recommendations. The freeze leaves the single biggest question hanging over the Israeli market unresolved.
Where this leaves 2026
The through-line of Israeli cannabis regulation is tension between two impulses: a public-health establishment that wants the program smaller, tighter and more clinical, and an industry-and-access coalition that wants it broader and cheaper. Both the tariff fight and the smokable-cannabis proposal are expressions of that tension, and both have stalled rather than resolved. For operators, patients and prospective buyers of the market's narrative, the regulatory environment is best described as actively contested.
This page summarises regulation for general information and is not legal advice. Rules change; verify current requirements with the Israeli Ministry of Health and the linked sources.
Related: Market overview · The major operators · Patient access
Compiled and reviewed by Tamar Levin, Editor. Sources are linked inline. This page is reviewed and refreshed periodically; it is informational and is not medical or legal advice.